$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

$ctxr Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000121390023010315 Filed on February 10, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2021 Q4
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.958M	$3.804M	$3.801M
YoY Change	43.98%	0.08%	92.96%
% of Gross Profit
Research & Development	$4.727M	$3.446M	$5.458M
YoY Change	36.92%	-36.87%	-11.83%
% of Gross Profit
Depreciation & Amortization	$730.00	$730.00	$730.00
YoY Change	0.0%	0.0%
% of Gross Profit
Operating Expenses	$10.69M	$7.250M	$9.259M
YoY Change	40.77%	-21.7%	13.47%
Operating Profit	-$10.69M	-$7.250M	-$9.259M
YoY Change	40.77%	-21.7%
Interest Expense	$303.3K	$214.6K	$33.98K
YoY Change	925.63%	531.4%	239.8%
% of Operating Profit
Other Income/Expense, Net	$303.3K	$3.800M
YoY Change
Pretax Income	-$10.38M	-$3.450M	-$9.225M
YoY Change	37.31%	-62.61%	13.19%
Income Tax	$144.0K	$144.0K
% Of Pretax Income
Net Earnings	-$10.53M	-$3.594M	-$9.225M
YoY Change	39.21%	-61.05%	13.24%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.07	-$0.02	-$0.06
Diluted Earnings Per Share	-$0.07	-$0.02	-$63.18K
COMMON SHARES
Basic Shares Outstanding	146.3M shares	146.2M shares	146.0M shares
Diluted Shares Outstanding	146.3M shares	146.2M shares	146.0M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$29.07M	$36.89M	$65.42M
YoY Change	-47.87%	-43.62%	1421.43%
Cash & Equivalents	$29.07M	$36.89M	$65.42M
Short-Term Investments
Other Short-Term Assets	$5.836M	$5.430M	$2.524M
YoY Change	133.13%	115.18%	94.12%
Inventory
Prepaid Expenses	$5.836M	$5.430M
Receivables
Other Receivables
Total Short-Term Assets	$34.90M	$42.32M	$67.94M
YoY Change	-40.09%	-37.72%	1113.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.639K	$3.370K	$786.2K
YoY Change	-99.64%	-99.57%	-12.64%
Goodwill	$9.347M	$9.347M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$38.06K	$38.06K	$38.06K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$69.34M	$69.39M	$69.57M
YoY Change	-0.27%	-0.26%	134.25%
TOTAL ASSETS
Total Short-Term Assets	$34.90M	$42.32M	$67.94M
Total Long-Term Assets	$69.34M	$69.39M	$69.57M
Total Assets	$104.2M	$111.7M	$137.5M
YoY Change	-18.43%	-18.77%	289.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.726M	$1.538M	$1.789M
YoY Change	59.85%	-14.06%	78.92%
Accrued Expenses	$2.251M	$690.4K	$5.552M
YoY Change	-2.85%	-87.57%	131.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.210M	$4.537M	$7.342M
YoY Change	54.4%	-38.2%	109.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$374.8K	$428.6K	$630.8K
YoY Change	-35.63%	-32.05%	-21.16%
Total Long-Term Liabilities	$374.8K	$428.6K	$630.8K
YoY Change	-35.63%	-32.05%	-36.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.210M	$4.537M	$7.342M
Total Long-Term Liabilities	$374.8K	$428.6K	$630.8K
Total Liabilities	$12.43M	$10.67M	$13.56M
YoY Change	22.02%	-21.29%	34.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$143.8M	-$133.3M
YoY Change
Common Stock	$146.4K	$146.2K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$91.21M	$100.4M	$124.0M
YoY Change
Total Liabilities & Shareholders Equity	$104.2M	$111.7M	$137.5M
YoY Change	-18.43%	-18.77%	289.56%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2021 Q4
OPERATING ACTIVITIES
Net Income	-$10.53M	-$3.594M	-$9.225M
YoY Change	39.21%	-61.05%	13.24%
Depreciation, Depletion And Amortization	$730.00	$730.00	$730.00
YoY Change	0.0%	0.0%
Cash From Operating Activities	-$7.853M	-$4.824M	-$4.652M
YoY Change	-18.75%	3.72%	-51.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	31.27K
YoY Change
NET CHANGE
Cash From Operating Activities	-7.853M	-$4.824M	-4.652M
Cash From Investing Activities
Cash From Financing Activities	31.27K
Net Change In Cash	-7.822M	-$4.824M	$0.00
YoY Change	-19.07%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$7.853M	-$4.824M	-$4.652M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2022Q4	dei	Document Type DocumentType	10-Q
CY2022Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q4	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	dei	Entity File Number EntityFileNumber	001-38174
CY2022Q4	dei	Entity Registrant Name EntityRegistrantName	Citius Pharmaceuticals, Inc.
CY2022Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3425913
CY2022Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Commerce Drive
CY2022Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	First Floor
CY2022Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranford
CY2022Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07016
CY2022Q4	dei	City Area Code CityAreaCode	(908)
CY2022Q4	dei	Local Phone Number LocalPhoneNumber	967-6677
CY2022Q4	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2022Q4	dei	Trading Symbol TradingSymbol	CTXR
CY2022Q4	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q4	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	146257797	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36887251	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41711690	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5430125	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2852580	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	42317376	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	44564270	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3370	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4100	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	599617	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646074	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2022Q3	us-gaap	Deposits Assets DepositsAssets	38062	usd
CY2022Q4	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2022Q3	ctxr	In Process Research And Development InProcessResearchAndDevelopment	59400000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	68784858	usd
CY2022Q4	us-gaap	Goodwill Goodwill	9346796	usd
CY2022Q3	us-gaap	Goodwill Goodwill	9346796	usd
CY2022Q3	us-gaap	Other Assets OtherAssets	68784858	usd
CY2022Q4	us-gaap	Assets Assets	111705221	usd
CY2022Q3	us-gaap	Assets Assets	113999302	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1537578	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1165378	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	690402	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1405394	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2107014	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1762251	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202178	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196989	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4537172	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4530012	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5705800	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5561800	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	428568	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481245	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10671540	usd
CY2022Q3	us-gaap	Liabilities Liabilities	10573057	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	146211130	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	146211130	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	146211130	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	146211130	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	146211	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	146211	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	233569202	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	232368121	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133282112	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129688467	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	100433301	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	102825865	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	600380	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101033681	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111705221	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113999302	usd
CY2022Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3445515	usd
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5457849	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2603287	usd
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2896749	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1201081	usd
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	904604	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	7249883	usd
CY2021Q4	us-gaap	Operating Expenses OperatingExpenses	9259202	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-7249883	usd
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-9259202	usd
CY2022Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	214549	usd
CY2021Q4	us-gaap	Investment Income Interest InvestmentIncomeInterest	33982	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3585689	usd
CY2022Q4	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3800238	usd
CY2021Q4	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	33982	usd
CY2022Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3449645	usd
CY2021Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9225220	usd
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	144000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3593645	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-9225220	usd
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2021Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146211130	shares
CY2021Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146012169	shares
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	103426245	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1201081	usd
CY2022Q4	us-gaap	Profit Loss ProfitLoss	-3593645	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	101033681	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	132782733	usd
CY2021Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	95884	usd
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	904604	usd
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-9225220	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	124558001	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-3593645	usd
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-9225220	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1201081	usd
CY2021Q4	us-gaap	Share Based Compensation ShareBasedCompensation	904604	usd
CY2021Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	95884	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	46457	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	42879	usd
CY2022Q4	us-gaap	Depreciation Depreciation	730	usd
CY2021Q4	us-gaap	Depreciation Depreciation	730	usd
CY2022Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	144000	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2577545	usd
CY2021Q4	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-217852	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	372200	usd
CY2021Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	512108	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-714992	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2514649	usd
CY2022Q4	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-344763	usd
CY2021Q4	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-327690	usd
CY2021Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-42698	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4824439	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4651522	usd
CY2022Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47488	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4824439	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4651522	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41711690	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70072946	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36887251	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65421424	usd
CY2020Q3	us-gaap	Shares Issued SharesIssued	7500000	shares
CY2022Q4	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	19400000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	40000000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	9346796	usd
CY2022Q4	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates </i>— Our accounting principles require our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting period. Estimates having relatively higher significance include the accounting for in-process research and development and goodwill impairment, stock-based compensation, valuation of warrants, and income taxes. Actual results could differ from those estimates and changes in estimates may occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	ctxr	Negative Cash Flow Operations NegativeCashFlowOperations	-4824439	usd
CY2022Q4	ctxr	Working Capital WorkingCapital	37800000	usd
CY2022Q2	us-gaap	Cost Maintenance CostMaintenance	90000	usd
CY2021Q2	us-gaap	Cost Maintenance CostMaintenance	90000	usd
CY2022Q4	us-gaap	Royalty Expense RoyaltyExpense	100000	usd
CY2022Q4	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	25000	usd
CY2022Q4	ctxr	Maximum Aggregate Annual Royalties MaximumAggregateAnnualRoyalties	150000	usd
CY2022Q4	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	1100000	usd
CY2022Q1	us-gaap	Cost Maintenance CostMaintenance	60000	usd
CY2021Q1	us-gaap	Cost Maintenance CostMaintenance	45000	usd
CY2022Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2034-01-02
CY2022Q4	ctxr	Developmental Milestone Description DevelopmentalMilestoneDescription	NoveCite is obligated to pay Novellus up to $51,000,000 upon the achievement of various regulatory and developmental milestones. NoveCite also must pay a royalty equal to low double-digit percentages of net sales, commencing upon the sale of a licensed product. This royalty is subject to downward adjustment to an upper-single digit percentage of net sales in any country in the event of the expiration of the last valid patent claim or if no valid patent claim exists in that country. The royalty will end on the earlier of (i) the date on which a biosimilar product is first marketed, sold, or distributed in the applicable country or (ii) the 10-year anniversary of the date of expiration of the last-to-expire valid patent claim in that country. In the case of a country where no licensed patent ever exists, the royalty will end on the later of (i) the date of expiry of such licensed product’s regulatory exclusivity and (ii) the 10-year anniversary of the date of the first commercial sale of the licensed product in the applicable country. In addition, NoveCite will pay to Eterna an amount equal to a mid-twenties percentage of any sublicensee fees it receives.
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.50	pure
CY2022Q4	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	Under the license agreement, Eisai is to receive a $6.0 million development milestone payment upon initial approval and additional commercial milestone payments related to the achievement of net product sales thresholds (which increases to $7 million in the event we have exercised our option to add India to the licensed territory prior to FDA approval) and an aggregate of up to $22 million related to the achievement of net product sales thresholds. We also are required to reimburse Eisai for up to $2.65 million of its costs to complete the ongoing Phase 3 pivotal clinical trial for I/ONTAK for the CTCL indication and reimburse Eisai for all reasonable costs associated with the preparation of a biologics license application (“BLA”) for I/ONTAK.
CY2022Q4	ctxr	Description Of License Agreement DescriptionOfLicenseAgreement	The term of the license agreement will continue until (i) if there has not been a commercial sale of a licensed product in the territory, until the 10-year anniversary of the original license effective date, March 30, 2016, or (ii) if there has been a first commercial sale of a licensed product in the territory within the 10-year anniversary of the original license effective date, the 10-year anniversary of the first commercial sale on a country-by-country basis. The term of the license may be extended for additional 10-year periods for all countries in the territory by notifying Eisai and paying an extension fee equal to $10 million.
CY2022Q4	ctxr	Sharebased Compensations Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term4 SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm4	P10Y
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9400171	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.07
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M21D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	869509	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3850000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13250171	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.83
CY2022Q4	ctxr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	169237	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6057254	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.18
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y11M15D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	169237	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	50000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.25
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	50000	shares
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.04
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.97
CY2022Q4	ctxr	Stock Options Vest Over Terms StockOptionsVestOverTerms	P10Y
CY2021Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	375000	shares
CY2021Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.04
CY2021Q4	ctxr	Board Of Directors Granted Options To Purchase Shares BoardOfDirectorsGrantedOptionsToPurchaseShares	200000	shares
CY2021Q4	us-gaap	Stockholders Equity Note Impact Of Conversion Of Contingently Convertible Securities On Diluted Earnings Per Share StockholdersEquityNoteImpactOfConversionOfContingentlyConvertibleSecuritiesOnDilutedEarningsPerShare	$1.87
CY2021Q4	ctxr	Share Issued Price Per Share ShareIssuedPricePerShare	1.72	shares
CY2022Q4	ctxr	Stockbased Compensation Expense Description StockbasedCompensationExpenseDescription	Stock-based compensation expense for the three months ended December 31, 2022 and 2021 was $1,201,081 (including $33,333 for the NoveCite Stock Plan) and $904,604 (including $33,333 for the NoveCite Stock Plan), respectively.
CY2022Q4	ctxr	Citius Stock Plans CitiusStockPlans	7877302	usd
CY2022Q4	ctxr	Weighted Average Period Term WeightedAveragePeriodTerm	P2Y1M6D
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2000000	shares
CY2021Q4	ctxr	Common Shares Outstanding CommonSharesOutstanding	2000000	shares
CY2021Q4	ctxr	Stock Option Plans Description StockOptionPlansDescription	As of December 31, 2022, NoveCite has options outstanding to purchase 2,000,000 common shares at a weighted average exercise price of $0.24 per share, of which 1,251,111 are exercisable. All of these options vest over 36 months and have a term of 10 years. The weighted average remaining contractual term of options outstanding under the NoveCite Stock Plan is 8.1 years. At December 31, 2022, unrecognized total compensation cost related to unvested awards under the NoveCite Stock Plan of $149,777 is expected to be recognized over a weighted average period of 1.2 years.
CY2022Q4	ctxr	Operating Lease Future Minimum Payments Due In Three Years OperatingLeaseFutureMinimumPaymentsDueInThreeYears	249024	usd
CY2022Q4	ctxr	Operating Lease Future Minimum Payments Due In Four Years OperatingLeaseFutureMinimumPaymentsDueInFourYears	253883	usd
CY2022Q4	ctxr	Number Of Warrants Issued NumberOfWarrantsIssued	38235864	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease	13250171	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	35000	shares
CY2022Q4	ctxr	Warrants Warrants	38235864	shares
CY2022Q4	ctxr	Common Stock Reserved CommonStockReserved	51521035	shares
CY2022Q4	ctxr	Schedule Lease Expense ScheduleLeaseExpense	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Lease cost</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,707</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">59,705</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Variable lease cost</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,158</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt">Total lease cost</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">60,865</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">59,705</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Weighted-average remaining lease term - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">2.8 Years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">3.8 Years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate - operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	59707	usd
CY2021Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	59705	usd
CY2022Q4	us-gaap	Variable Lease Cost VariableLeaseCost	1158	usd
CY2022Q4	us-gaap	Lease Cost LeaseCost	60865	usd
CY2021Q4	us-gaap	Lease Cost LeaseCost	59705	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q4	ctxr	Operating Lease Future Minimum Payments Due Current OperatingLeaseFutureMinimumPaymentsDueCurrent	183427	usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q4	ctxr	Operating Lease Future Minimum Payments Due OperatingLeaseFutureMinimumPaymentsDue	707794	usd
CY2022Q4	ctxr	Operating Lease Future Minimum Payments Due In Five Years OperatingLeaseFutureMinimumPaymentsDueInFiveYears	21460	usd
CY2022Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	ctxr	Less Interest LessInterest	-77048	usd
CY2022Q4	ctxr	Present Value Of Lease Liabilities PresentValueOfLeaseLiabilities	630746	usd
CY2022Q4	ctxr	Schedule Operating Leases Assets And Liabilities ScheduleOperatingLeasesAssetsAndLiabilities	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1.5pt solid">Leases</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Classification</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30,<br/> 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt">Lease asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt; text-align: center"> </td><td style="width: 9%; padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">Operating</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">599,617</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">646,074</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total lease assets</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">599,617</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">646,074</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span style="font-size: 10pt">Operating</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">202,178</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">196,989</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Non-current</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-size: 10pt">Operating</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">428,568</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">481,245</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total lease liabilities</td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: center"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">630,746</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">678,234</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	599617	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	646074	usd
CY2022Q4	ctxr	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	599617	usd
CY2022Q3	ctxr	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	646074	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202178	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196989	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	428568	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	481245	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	630746	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	678234	usd
CY2022Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	13250	usd
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	16826	usd
CY2022Q4	us-gaap	Discontinued Operation Amount Of Adjustment To Prior Period Gain Loss On Disposal Before Income Tax DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax	3585689	usd
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	12000000	shares
CY2022Q4	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	35000	shares
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Maximum Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsMaximumNumberOfShares	12035000	shares
CY2021Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2021Q4	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2021Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2022Q4	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2022Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001506251

Files In Submission

Name	View Source	Status
0001213900-23-010315-index-headers.html	Edgar Link	pending
0001213900-23-010315-index.html	Edgar Link	pending
0001213900-23-010315.txt	Edgar Link	pending
0001213900-23-010315-xbrl.zip	Edgar Link	pending
ctxr-20221231.xsd	Edgar Link	pending
f10q1222ex31-1_citiuspharma.htm	Edgar Link	pending
f10q1222ex31-2_citiuspharma.htm	Edgar Link	pending
f10q1222ex32-1_citiuspharma.htm	Edgar Link	pending
f10q1222_citiuspharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
ctxr-20221231_def.xml	Edgar Link	unprocessable
ctxr-20221231_lab.xml	Edgar Link	unprocessable
ctxr-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ctxr-20221231_cal.xml	Edgar Link	unprocessable
f10q1222_citiuspharma_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr

2023 Q1 Form 10-Q Financial Statement

#000121390023010315 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR Citius Pharmaceuticals, Inc. Stock $ctxr

2023 Q1 Form 10-Q Financial Statement

#000121390023010315 Filed on February 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTXR
Citius Pharmaceuticals, Inc. Stock $ctxr